News

Brian Frederick, PhD, discusses how the short life expectancy after diagnosis leads many patients with ALS to lose their lives before receiving disability benefits.

Biohaven executives remain optimistic about the slight but insignificant improvement observed in those with mild AD.

The clinical fellow at Massachusetts General Hospital gives his call to action on how what needs to change to improve EEG education among residency programs.

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

Creative Medical Technology’s ImmCelz contrasts other stem cell-based approaches by utilizing stem cells outside of the body to reprogram the patient’s own immune cells.

Researchers hope that R-loop modulation may hold potential in the future treatment of ALS.

The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.

If approved, adaptive DBS could be added to Medtronic’s Percept device, which was approved in June 2020.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

Researchers developed and trained a random forest classifier that resulted in high precision and accuracy as a screening tool for those with mild cognitive impairment.

Researchers sought to redefine dichotomous classifications of MS and identified meaningful classifications.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine provided background on a recently completed study correlating sleep and cognitive decline.

Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervates muscles throughout the body.

Brian Wainger, MD, PhD, assistant professor of neurology and anesthesiology, Harvard Medical School, discussed the recently published phase 2 trial a repurposed epilepsy drug in patients with ALS.

No significant between-group differences were detected in symptomatic intracerebral hemorrhage or 90-day mortality.

Rafael Carbunaru, PhD, MSc, vice president, research and development, Neuromodulation, Boston Scientific, discussed the system’s recent FDA approval.

The clinical fellow at Massachusetts General Hospital discussed the idea of standardizing the number of EEG reads residents should be required to do before their training is complete.

After winning FDA approval in October 2020, the new expanded indication includes adolescents aged 12 and older with episodic or chronic migraine.

Veronica Hood, PhD, writes a recap of research and treatments for epilepsy presented at the meeting.

Here's what is coming soon to NeurologyLive.

Patients with SCD and schizophrenia specifically had increased risk of developing Parkinson disease later in life.

The Dravet Syndrome Foundation offers a list of online resources for patient families.

The chief medical officer at SanBio discussed how the investigational agent SB623 can fill the void of disease-modifying therapies for TBI.

A parent's perspective of the Partners Against Mortality in Epilepsy (PAME) 2020 meeting.

Physicians from Stanford Children’s Health offer their keys to successful pediatric neuroscience teams and what to focus on to provide a better quality of life for children.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.